Originalie
Cunningham D et al. Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial. Lancet Oncol. 2013;14(11):1077-85.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Schalhorn, A. Bevacizumab-Addition zu Capecitabin verlängert progressionsfreies Überleben. Info Onkol. 17, 16–17 (2014). https://doi.org/10.1007/s15004-014-0802-5
Published:
Issue Date:
DOI: https://doi.org/10.1007/s15004-014-0802-5